Dr. Kaplan has over 25 years of experience in drug development in the biotechnology industry. She currently serves as Chief Development Officer with ProMIS Neurosciences, a company developing therapies for neurodegenerative disorders. Prior to these appointments, Dr. Kaplan held positions of increasing responsibility at Genzyme Corporation, most recently as a Vice President of Research, in the fields of neuroimmunology, cancer immunotherapy, gene therapy, and autoimmunity. She led the work of the Research Team supporting the approval and launch of Lemtrada and Aubagio for the treatment of relapsing-remitting multiple sclerosis. Prior to joining Genzyme, she was an Associate Immunopathologist at SmithKline Beecham where she established an immunotoxicology program. Her work has resulted in over 70 scientific publications and multiple patents. Dr. Kaplan holds a Ph.D. in Microbiology & Immunology from McGill University in Montreal, Canada and conducted post-doctoral studies at the Albert Einstein College of Medicine in New York.